Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Dr. Zhiwei Hu is an associate professor in the Department of Surgery of The Ohio State University College of Medicine. Prior to this position, he was a Research Scientist (Research Associate Professor) in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine. Dr. Hu is one of first few scientists who proposed to target both the tumor cells and tumor neovasculature. Subsequently he successfully co-invented/developeda novel Icon molecule for dual neovascular- and cancer cell-targeted immunotherapy. As co-inventor, he holds 4 US patents of Icon and its uses. The Icon has been tested for immunotherapy of cancer, aged-related macular degeneration (AMD) and endometriosis in preclinical studies. Icon immunotherapy is currently being tested in Phase I clinical trials for AMD patients. Recently his laboratory developed another targeted therapeutics, namely factor VII (fVII)-targeted photodynamic therapy (fVII-tPDT) using fVII peptides-conjugated photosensitizers for cancer (including chemoresistant cancer) and AMD. He is a member of the Yale Cancer Center, American Association for Cancer Research, and The American Association of Immunologists. He is an Adjunct Professor of Sichuan University School of Medicine and Nanchang University School of Medicine in China, and a Scientific Advisor for Iconic Therapeutics Inc. In 2011 he was elected as Vice President of the Chinese Association for Science and Technology in Connecticut (CAST-CT). Dr. Hu is a peer reviewer for numerous scientific journalsin immunology, photodynamic therapy and cancer research and serves as an editorial board member of The Journal of Immune Based Therapies, Vaccines and Antimicrobials, The Journal of Analytical &Bioanalytical Techniques, Advances in Breast Cancer Research, Open Journal of Immunology, Open Journal of Apoptosis, The Journal of Cancer Research and Treatment and Dataset Papers in Medicine. Starting February 2012, he serves as Editor-in-Chief of The Journal of Analytical &Bioanalytical Techniques.
Tumor Immunology, Natural Killer Cells, Antibody Immunotherapy, Adenoviral Gene Therapy, Targeted Photodynamic Therapy, Tumor Angiogenesis, Tumor Stem Cells, Molecular Biology, DNA Recombinant Techniques, Phage Display AntibodyNetwork
Prof Xuping Sun has received his PhD in Chinese Academy of Sciences University in 2005. Currently, he is working as Adjunct Professor in King Abdulaziz University. He is serving as an editorial member of several reputed journals like American Journal of Nanotechnology and International Journal of Genuine Traditional Medicine. He has more than 100 papers to his credit published in various international journals and conferences.He is honoured as National Excellent Doctoral Dissertation for his research.
Prof. Xuping Sun is working on bionanotechnology and functional materials. Currently, his research interests have been focused on Nanoelectrochemistry, DNA nanotechnology, Biochip, Nanomedicine, Supramolecular chemistry, Materials chemistry, Photocatalysis and photoelectrochemistry.Network
Professor Andy Benniston started his career at Warwick University (UK) where he obtained a 1st in Chemistry (Hons) in 1987 and a PhD in 1990 with Professor Peter Moore. He spent one year in Strasbourg with Dr Jean-Pierre Sauvage on a Royal Society Fellowship, and this was followed by a stay in Austin Texas at the Center for Fast Kinetics Research with Dr Tony Harriman. After spending around six years as a lecturer in the Chemistry Department at the University of Glasgow he moved to Newcastle University in 2001 to set up the Molecular Photonics Laboratory. Promotion to Senior Lecturer in 2003 was followed by appointment in 2011 to the Professor of Photonic Energy Sciences, with special research emphasis on the discovery of new solutions to problems in fields covering biology (real-time diagnostics) and chemistry (light-to-chemical fuel energy storage).
Andy Benniston has worked on many different aspects of chemistry, studying in the early years the coordination chemistry of macrocycles and redox-active ligands for transition metal ion sensing. Back in 1993 he produced one of the first light-activated molecular shuttles, and prepared and studied several novel merocyanine dyes for photodynamic therapy applications. Other work has focussed on the study of photoactive metal-based catenanes, energy and electron transfer through molecular bridges, picosecond transient resonance Raman for studying charge transfer complexes, artificial zinc enzymes, molecular switches and fluorescent probes.
More recently special attention has focused on the use of borondipyrromethene (Bodipy) dyes for fluorescence-based applications in reactive oxygen sensing (ROS), neural imaging, and as rheology probes for in-situ viscosity measurements.
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals